Filing Flows › Abbott Laboratories (ABT) › Guidance & outlook
Abbott Laboratories (ABT) guidance and outlook
Abbott Laboratories (ABT) lowered its guidance on Oct 21, 2026: Revenue +6% for FY2026; EPS $5.50–$5.55 for FY2026; EPS $1.62–$1.67 for Q4 2026. Abbott Laboratories' 10-K filed Feb 20, 2026 makes 3 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +6% | lowered |
| EPS | FY2026 | $5.50–$5.55 | reaffirmed |
| EPS | Q4 2026 | $1.62–$1.67 | new |
From the earnings release filed Oct 21, 2026 (8-K on EDGAR).
Forward-looking statements, 10-K filed Feb 20, 2026
- In 2025, Abbott management approved plans to streamline certain operations in order to reduce costs and improve efficiencies in its Diagnostics, Nutritionals, Established Pharmaceuticals, and Medical Devices businesses.
- In 2024, Abbott management approved plans to streamline certain operations in order to reduce costs and improve efficiencies in its Diagnostics, Medical Devices, Established Pharmaceuticals, and Nutritionals businesses, including the discontinuation of its ZonePerfect product line.
- In 2023, Abbott management approved plans to restructure various operations in order to reduce costs in its Medical Devices, Diagnostics, and Established Pharmaceuticals businesses.
Abbott Laboratories' latest quarter
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart follows the revenue to costs, profit and cash.
Questions
Did Abbott Laboratories raise or lower its guidance?
Abbott Laboratories (ABT) lowered its guidance on Oct 21, 2026: Revenue +6% for FY2026; EPS $5.50–$5.55 for FY2026; EPS $1.62–$1.67 for Q4 2026.
What does Abbott Laboratories expect?
In 2025, Abbott management approved plans to streamline certain operations in order to reduce costs and improve efficiencies in its Diagnostics, Nutritionals, Established Pharmaceuticals, and Medical Devices businesses. In 2024, Abbott management approved plans to streamline certain operations in order to reduce costs and improve efficiencies in its Diagnostics, Medical Devices, Established Pharmaceuticals, and Nutritionals businesses, including the discontinuation of its ZonePerfect product line. In 2023, Abbott management approved plans to restructure various operations in order to reduce co
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.